ru treatmentoptions htm

Скачать 0.67 Mb.

Название	Http://www autismwebsite com/ari/russian/ru treatmentoptions htm
страница	5/5
Дата конвертации	10.04.2013
Размер	0.67 Mb.
Тип	Документы

Содержание

American Family Physician

1 2 3 4 5

Clinical Pharmacology, 1991 Dec; 10(12):914-22.

14. Jorgensen FM: Succimer: the first approved oral lead chelator,^ American Family Physician, 1993 Dec; 48(8):1495-1502.

15. A. Holmes, S. Cave, J. El-Dahr, Open Trial of Chelation of Children with Autism, presentation at the 2002 International Meeting for Autism Research.

16. Chauhan A, Chauhan V, Brown WT, Cohen I. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin--the antioxidant proteins. Life Sci. 2004 Oct 8;75(21):2539-49.

17. McGinnis WR Oxidative stress in autism. Altern Ther Health Med. 2004 Nov-Dec;10(6):22-36; quiz 37, 92.

18. Pingree SD, Simmonds PL, Woods JS. Effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) on tissue and urine mercury levels following prolonged methylmercury exposure in rats. Toxicol Sci. 2001 Jun;61(2):224-33.

19. Hurlbut KM, Maiorino RM, Mayersohn M, Dart RC, Bruce DC, Aposhian HV Determination and metabolism of dithiol chelating agents. XVI: Pharmacokinetics of 2,3-dimercapto-1-propanesulfonate after intravenous administration to human volunteers. J Pharmacol Exp Ther. 1994 Feb;268(2):662-8.

20. Maiorino RM, Dart RC, Carter DE, Aposhian HV, Determination and Metabolish of Dithiol Chelating Agents. XII. Metabolism and Pharmacokinetics of Sodium 2,3-Dimercaptopropane-1-Sulfonate in Humans. J. Pharm. Exp. Therapeutics 1991 259:808-814.

21. Buttar RA, Autism: The Misdiagnosis of our Future Generations, US Congressional Sub-Committee on Wellness and Human Rights, Washington, D.C., May 6 2004.

22. Lonsdale D, Shamberger R J, Audhya T. Treatment of autistic spectrum children with thiamine tetrahydrofurfuryl disulfide: a pilot study. Neuroendocrinol Lett 2002;23:303-308.

23. Fang X, Fernando Q: A comparative study ofmeso- andrac- 2,3 dimercaptosuccinic acids and their zinc complexes in aqueous solution,Chemical Research in Toxicology, 1994 Nov-Dec; 7(6):770-8.

24. Flora SJ, Tandon SK: Beneficial effects of zinc supplementation during chelation treatment of lead intoxication in rats,Toxicology, 1990 Nov; 64(2):129-39.

25. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry. 1993 Sep;17(5):765-74

26. Tan DX,et al: Significance of melatonin in antioxidative defense systems: reaction and products,Biological Signals & Receptors 2000 May-Aug;9(3-4):137-59.

27. Olivieri G,et al: Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells,Journal of Neurochemistry 2000 Jan;74(1):231-6.

28. Martin M,et al: Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium redin vivo,Journal of Pineal Research, 2000 May; 28(4):242-8.

29. Gordon N: The therapeutics of melatonin: a pediatric perspective,Brain & Development 2000 Jun;22(4):213-7.

30. Witschi A,et al: The systemic availability of oral glutathione,European Journal of Clinical Pharmacology 1992;43(6):667-9.

31. Ziegler C,et al: Alpha-lipoic acid in the treatment of diabetic neuropathy in Germany: current evidence from clinical trials,Experimental & Clinical Endocrinology & Diabetes 1999;107(7):421-30.

32. Ziegler C,et al: Alpha-lipoic acid in the treatment of diabetic neuropathy in Germany: current evidence from clinical trials,Experimental & Clinical Endocrinology & Diabetes 1999;107(7):421-30.

33. Gregus Z,et al: Effect of lipoic acid on biliary excretion of glutathione and metals,Toxicology & Applied Pharmacology 1992 May;114(1):88-96.

34. Smith DR,et al: Succimer and the urinary excretion of essential elements in a primate model of childhood lead exposure,Toxicological Sciences 2000 Apr;54(2):473-80.

35. Ding GS, Liang YY: Antidotal effects of dimercaptosuccinic acid,Journal of Applied Toxicology, 1991 Feb; 11(1):7-14.

36. Yim CY,et al: Use of N-acetylcysteine to increase intracellular glutathione during induction of antitumor responses by IL-2,Journal of Immunology, 1994 Jan 15; 152(12):5796-805.

37. Meyer A, Buhl R, Magnussen H: The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis,European Respiratory Journal, 1994 Mar; 7(3):431-6.

38. Scheinberg H "Wilson's Disease" Chapt. 348 in Harrison's Principles of Internal Medicine" Isselbacher et al. eds, 13the Ed., McGraw-Hill (1994) 2090

39. Lipsky PE "Rheumatoid Arthritis" Chapt. 285 in Harrison's Principles of Internal Medicine Isselbacher et al. eds, 13the Ed., McGraw-Hill (1994) 1654

40. Rosenberg LE and Short EM "Inherited Defects of Membrane Transport" Chapt. 353 in Harrison's Principles of Internal Medicine Isselbacher et al. eds, 13the Ed., McGraw-Hill (1994) 2128

41. Graef JW "Heavy Metal Poisoning" Chapt 396 in Harrison's Principles of Internal Medicine Isselbacher et al. eds, 13the Ed., McGraw-Hill (1994) 2564, 65

42. Drug Facts and Comparisons, Wolters Kluwer Health, St. Louis MO June 1991 714-717

43. Wilson JD "Vitamin Deficiency and Excess" Chapter 77 in Harrison's Principles of Internal Medicine op. cit. 475

44. ARI Parent Response Tally, ARI Publication 34/August 2004 n=5495, 47% improved, 49% no effect, 4% worsened behavior

45. Graef JW, "Heavy Metal Poisoning" Chapt 396 in Harrison's Principles of Internal Medicine Isselbacher et al. eds, 13the Ed., McGraw-Hill (1994) 2465

46. D. Quig, Doctor’s Data, private communication.

47. Toxicological Profile for Mercury, US Department of Health and Human Services, Agency for Toxic Substances and Disease Registry, 1999, section 1.6.

48. Dally A. The rise and fall of pink disease. Soc Hist Med. 1997 Aug;10(2):291-304.

49. Mahaffey KR, Clickner RP, Bocurow CC, Blood Organic Mercury and Dietary Mercury Intake: National Health and Nutrition Examination Survey, 1999 and 2000, Env. Health Persp. 112(5) 562-570.

50. J.G. Hursh, MG Cheian, JJ Vostal, R. Vander Mallie, Clearance of mercury vapor inhaled by human subjects. Arch. Environ. Health 31:302-309 (1976).

51. J.E. Patterson, B.G. Weissberg, P.J. Dennison. Mercury in human breath from dental amalgams. J. Den. Res 60 (1981) 1668-1671.

52. S. Langworth, K-G Kohlbeck, A. Akesson, Sed. Dent J. 12 (1988) 71-72.

53. A. Berglund Estimaton by a 24-hour study of the daily dose of intra-oral mercury vapor inhaled after release from dental amalgam, J. Dent Res 69 (1990) 1646-1651

54. Thimerosal in Vaccines—An Interim Report to Clinicians (RE9935), American Academy of Pediatrics Policy Statement, Volume 104. Number 3, September 1999, 570-574.

55. Hornig M, Chian D, Lipkin WI Neurotoxic effects of postnatal thimerosal are mouse strain dependent, Mol. Psych. (2004) 9(9):833-45.

56. Bernard S, Enayati A, Redwood L, Roger H, Binstock T. Autism: a novel form of mercury poisoning, Med. Hypotheses 56(4): 462-471, 2001.

57. Holmes AS, Blaxill MF and Haley BE (2003) ‘Reduced Levels of Mercury in First Baby Haircuts of Autistic Children’,Int. J. Toxicology 22(4) 277-285.

58. Adams JB, Mercury and Autism, Presentation at the July 2004 Annual Meeting of the Autism Society of America.

59. Bradstreet J, Geier DA, Harrison HH, Kartzinel JJ, Clark AD, Adams JB, Geier MR. An Evaluation of the Relationship between Thimerosal, Childhood Developmental Disorders and Biological Markers for Mercury Susceptibility, in submission.

60. Audhya T, Nutritional Abnormalities in children with Autism, May 2004 AutismOne Conference in Chicago, IL.

61. Haley B, Presentation at September 2004 DAN! Conference, San Diego, CA.

62. Adams JB, A Review of the Autism-Mercury Connection, Conference Proceedings of the Annual Meeting of the Autism Society of America, July 2004.

63. Ip P, Wong V, Ho M, Lee J, Wong W Mercury exposure in children with autistic spectrum disorder: case-control study. J Child Neurol. 2004 Jun;19(6):431-4.

64. Adams J.B., Holloway C.E., George F, Quig D., Toxic Metals and Essential Minerals in the Hair of Children with Autism and their Mothers, in submission.

65. Geier DA, Geier MR. An assessment of the impact of thimerosal on childhood neurodevelopmental disorders. Pediatr Rehabil. 2003 Apr-Jun;6(2):97-102.

66. Geier MR, Geier DA. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med (Maywood). 2003 Jun;228(6):660-4.

67. Geier M.R. and Geier D.A., Thimerosal in Childhood Vaccines, Neurodevelopment Disorders, and Heart Disease in the United States, J. American Physicians Surgeons 8(1) 6-11 2003.

68. Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B.Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association. Pediatrics. 2004 Sep;114(3):584-91.

69. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA. 2003 Oct 1;290(13):1763-6.

70. Madsen KM, Lauritsen MB, Pedersen CB, Thorsen P, Plesner AM, Andersen PH, Mortensen PB. Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Pediatrics. 2003 Sep;112(3 Pt 1):604-6.

71. Stehr-Green P, Tull P, Stellfeld M, Mortenson PB, Simpson D. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med. 2003 Aug;25(2):101-6.

72. Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, Shinefield H, Chen RT. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics. 2003 Nov;112(5):1039-48.

73. Zabinski Z: The activity of erythrocyte enzymes and basic indices of peripheral blood erythrocytes from workers chronically exposed to mercury vapors,Toxicology & Industrial Health 2000 Feb;16(2):58-64.

74. Gerr F, Frumkin H, Hodgins P: Hemolytic anemia following succimer administration in a glucose-6-phosphate dehydrogenase deficient patient,Journal of Toxicology – Clinical Toxicology 1994;32(5):569-75.

75. Zabinski Z: The activity of erythrocyte enzymes and basic indices of peripheral blood erythrocytes from workers chronically exposed to mercury vapors,Toxicology & Industrial Health 2000 Feb;16(2):58-64.

76. Woods JS, Fowler BA: Renal porphyrinuria during chronic methyl mercury exposure,Journal of Laboratory & Clinical Medicine 1977 Aug;90(2):266-72.

77. Woods JS: Altered porphyrin metabolism as a biomarker of mercury exposure and toxicity,Canadian Journal of Physiology & Pharmacology 1996 Feb;74(2):210-215.

78. Vinay SP, Raghn KG, Sood PP: Dose and duration related methylmercury deposition, glycosidase inhibition, myelin degeneration and chelation therapy,Cellular and Molecular Biology, 1990; 36(5):609-23.

79. Gong Z, Evans HL: Effect of chelation withmeso-dimercaptosuccinic acid (DMSA) before and after the appearance of lead-induced neurotoxicity in the rat,Toxicology & Applied Pharmacology, 1997 Jan; 144(2):205-14.

80. McCourtie J, Douglas LJ: Relationship between cell surface composition of Candida albicans and adherence to acrylic after growth on different carbon sources,Infection & Immunity 1981 Jun; 32(3):1234-41.

81. Burke V, Gracey M: An experimental model of gastrointestinal candidiasis,Journal of Medical Microbiology, 1980 Feb; 13(1):103-10.

82. Jeske J,et al: Evaluation of therapeutic efficacy of ketoconazole and itraconazole in the treatment of alimentary tract candidiasis,Medical Science Monitor, 1999 5(1):141-145.

83. Metzger S, Hoffman H: Fluconazole-resistant Candida specimens from HIV-infected patients with recurrent Candida stomatitis: Crossresistance to itraconazole and ketoconazole,Mycoses, 1997 Supp. 40(1):56-63.

84. Velentin A,et al: Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model,Antimicrobial Agents & Chemotherapy, 1996 40(6):1342-1345.

²[1] Не выявлено перекрестной взаимосвязи между DMSA и сульфамидными антибиотиками. Если у пациента есть чувствительность или аллергия на другие дитиоловые хелаты (такие как DMPS , DMPA , dimercaprol / BAL ), то его нельзя подвергать DMSA терапии, хотя все зависит от степени тяжести реакции. В том случае, если реакция слабая или сомнительная, можно дать небольшую тестовую дозу, что поможет принять окончательное решение.

Токсический некролиз кожи и эритема возникают без всяких видимых причин, их этиология остается непонятной. Они могут возникать и в начале лечения, и через несколько месяцев после начала. Оба эти заболевания в единичных случаях фиксируются в связи с DMSA , хотя десятки тысяч детей принимали это лекарство. Эритема multiforme (синдром Стивена-Джонсона) – самокупирующееся воспалительное заболевание кожи и слизистой. Предположительно болезнь вызывается нарушениями в иммунной системе и лимфоцитах. Симптомы эритемы – характерные круглые язвы на коже, воспаление в горле, язвы на слизистой и температура. Болезнь обычно начинается через неделю или больше после начала терапии и, обычно, сама собой прекращается, если больной больше не принимает вызывающих ее медикаментов. Однако, она может вызвать кожно-слизистые осложнения, лечение которых может занять недели.

Токсический эпидермальный некролиз ( TEN ) является наиболее тяжелым кожным заболеванием, которое появляется в ответ на прием лекарства и может стать смертельным, если вовремя его не распознать. Приступ его обычно очень острый, характеризуется некрозом кожи без каких-либо воспалений. Происхождение заболевания неясно, но оно также внезапно прекращается после прекращения приема вызывающих его лекарств. У нас нет никакого специального лечения кроме поддерживающий терапии и облегчения симптомов.

1 2 3 4 5

плохо

не очень плохо

средне

хорошо

отлично

Ваша оценка этого документа будет первой.

Ваша оценка:

	Http://www rusmedserv com/mycology/html/runke htm		Http://journals medi ru/92. htm Актуальные вопросы акушерства и гинекологии http://gyna medi ru/ag11.
	Http://www ellink ru/co/vita/c 11. htm Глинолечение-один из высокоэффективных естественных природных методов лечения. Применяется в медицине...		Http://narrativ boom ru/library htm
	Http://www imedis ru		Http://www imedis ru
	Http://www imedis ru		Http://www imedis ru
	Http://www imedis ru		Http://www superfoods com ua

Http://www autismwebsite com/ari/russian/ru treatmentoptions htm

Похожие: